Publications by authors named "Michelle A Rudek"

Claim this Profile
R
Reversible chemoresistance of pancreatic cancer grown as spheroids.
Yoshihisa Matsushita, Alexis Norris, Yi Zhong, Asma Begum, Hong Liang, Michelle A Rudek

J Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek

Sci Transl Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.
Susan C Scott, Anna Farago, W Victoria Lai, Marianna Zahurak, Michelle A Rudek

Cancer Chemother Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Keri R Maher, Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng, Michelle A Rudek

Cancer Chemother Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma.
Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek

medRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer.
Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai, Vikrant Palande, Michelle A Rudek

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.
Evanthia T Roussos Torres, Won J Ho, Ludmila Danilova, Joseph A Tandurella, James Leatherman, Michelle A Rudek

Nat Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
Karisa C Schreck, Roy E Strowd, Louis B Nabors, Benjamin M Ellingson, Michael Chang, Michelle A Rudek

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nelfinavir inhibition of Kaposi's sarcoma-associated herpesvirus protein expression and capsid assembly.
Maggie Li, Barbara J Smith, Jaeyeun Lee, Jennifer Petr, Nicole M Anders, Michelle A Rudek

Infect Agent Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor.
Michael T Davis, Nicole M Anders, A Dimitrios Colevas, Troy E Messick, Michelle A Rudek

Biomed Chromatogr· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087).
Missak Haigentz, Jeannette Y Lee, Elizabeth Y Chiao, David M Aboulafia, Lee Ratner, Michelle A Rudek

Clin Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Ryan D Gentzler, Liza C Villaruz, John C Rhee, Bethany Horton, Joseph Mock, Michelle A Rudek

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method.
Zahra Talebi, Dominique A Garrison, Eric D Eisenmann, Kalindi Parmar, Geoffrey I Shapiro, Michelle A Rudek

Heliyon· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Amanda B Kagan, Dominique A Garrison, Nicole M Anders, Jonathan A Webster, Sharyn D Baker, Michelle A Rudek

Clin Transl Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Paul G Rubinstein, Page C Moore, Milan Bimali, Jeanette Y Lee, Michelle A Rudek

Lancet Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting hypoxia-inducible factors with 32-134D safely and effectively treats diabetic eye disease in mice.
Jing Zhang, Deepti Sharma, Aumreetam Dinabandhu, Jaron Sanchez, Brooks Applewhite, Michelle A Rudek

J Clin Invest· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative.
Amanda B Kagan, Blake S Moses, Rena Lapidus, Bryan T Mott, Ganesha Rai, Michelle A Rudek

Cancer Chemother Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.
Ravi K Anchoori, Vidyasagar Anchoori, Brandon Lam, Ssu-Hsueh Tseng, Samarjit Das, Michelle A Rudek

PLoS One· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Testing: Time to Put Patient Safety First.
Sharyn D Baker, Susan E Bates, Gabriel A Brooks, William L Dahut, Robert B Diasio, Michelle A Rudek

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Danielle Shafer, Amanda B Kagan, Michelle A Rudek, Maciej Kmieciak, Mary Beth Tombes

Cancer Chemother Pharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month effective treatment of corneal graft rejection.
Tuo Meng, Jinhua Zheng, Min Chen, Yang Zhao, Hadi Sudarjat, Michelle A Rudek

Sci Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults.
Jessica L Lee, Cissy Zhang, Reyhan Westbrook, Mariann M Gabrawy, Lolita Nidadavolu, Michelle A Rudek

J Gerontol A Biol Sci Med Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of navtemadlin in human plasma and brain tissue by liquid chromatography-tandem mass spectrometry.
Amanda B Kagan, Nicole M Anders, Avelina Hemingway, Eudocia Q Lee, Kevin R Kelly, Michelle A Rudek

Biomed Chromatogr· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Clinical Pharmacy Services for Phase 1 Clinical Trials.
Jacqueline Saunders, Sumati Murli, Michelle A Rudek, Anand Khandoobhai, Anne DeLisa

J Hematol Oncol Pharm· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.
Shaima Salman, David J Meyers, Elizabeth E Wicks, Sophia N Lee, Emmanuel Datan, Michelle A Rudek

J Clin Invest· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis